372 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Is Ironwood's Growth About to Slow? https://www.fool.com/investing/general/2017/06/05/is-ironwoods-growth-about-to-slow.aspx?source=iedfolrf0000001 Jun 05, 2017 - New competition could slow prescription growth for Linzess and take some of the luster off this small-cap biotech stock.
Aerie's Ophthalmic Candidate Positive in Registration Trial http://www.zacks.com/stock/news/261948/aeries-ophthalmic-candidate-positive-in-registration-trial?cid=CS-ZC-FT-261948 May 25, 2017 - Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter https://www.fool.com/investing/2017/05/22/3-drug-stocks-billionaire-money-managers-dumped-bi.aspx?source=iedfolrf0000001 May 22, 2017 - Billionaires appear to have focused on drug stocks that were mired in debt in Q1.
Agnes Scott President Elizabeth Kiss to step down June 2018 http://feeds.bizjournals.com/~r/industry_14/~3/UT2FaHIaO34/agnes-scott-president-elizabeth-kiss-to-step-down.html May 22, 2017 - Agnes Scott College President Elizabeth Kiss sent an email to the institution’s alumnae announcing her intention to resign on June 30, 2018 – completing a dozen years at the helm of the Decatur liberal arts women’s college. “Agnes Scott is a magical place, and I feel so blessed to have had the privilege of serving as your president for the past 11 years,” Kiss wrote in her email. “From the moment I first read Agnes Scott’s powerful mission statement, I felt a deep sense of connection…
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab http://www.zacks.com/stock/news/261265/amgen-amgn-submits-bla-to-fda-for-migraine-drug-erenumab?cid=CS-ZC-FT-261265 May 19, 2017 - Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Allergan's Irritable Bowel Drug Viberzi Approved in Canada http://www.zacks.com/stock/news/260911/allergans-irritable-bowel-drug-viberzi-approved-in-canada?cid=CS-ZC-FT-260911 May 17, 2017 - Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss http://www.zacks.com/stock/news/260909/cardiome-crme-q1-loss-wider-than-expected-sales-miss?cid=CS-ZC-FT-260909 May 17, 2017 - Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka http://www.zacks.com/stock/news/260741/teva-teva-launches-glumetza-generic-inks-deal-with-otsuka?cid=CS-ZC-FT-260741 May 16, 2017 - Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls http://www.zacks.com/stock/news/260350/teva-teva-q1-earnings-in-line-sales-lag-as-copaxone-falls?cid=CS-ZC-FT-260350 May 12, 2017 - Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Actavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher https://www.fool.com/investing/2017/05/11/actavis-generics-acquisition-drives-teva-pharmaceu.aspx?source=iedfolrf0000001 May 11, 2017 - The specialty and generic drugmaker gets another boost from its 2016 purchase of Actavis Generics from Allergan.

Pages: 1...2627282930313233343536...38

<<<Page 31>